Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022

PARSIPPANY, N.J.–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Keith Westby, Chief Operating Officer, will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9, 2022, at 1:45 p.m. Eastern Time. Investors and the general public are invited to access the … [Read more…]

Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance

Second-Quarter 2022 Results: — Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million — — GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million — — TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million — — KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Million — — Cash Position of … [Read more…]

Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, Aug. 10, 2022, … [Read more…]

AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients

Atlas’ stealth-stage company will leverage AbCellera’s technology to start and advance new drug programs with enhanced speed and capital efficiency VANCOUVER, British Columbia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$ABCL—AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage … [Read more…]

Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

– Expect to complete SER-109 Biologics License Application filing in the coming weeks – – Reported confirmatory SER-109 Phase 3 study results, including in individuals with a first recurrence of C. difficile infection – – Strengthened balance sheet with $100 million registered direct equity offering – Conference call at 8:30 a.m. ET today – CAMBRIDGE, … [Read more…]

Charles River Laboratories Announces Second-Quarter 2022 Results

– Second-Quarter Revenue of $973.1 Million – – Second-Quarter GAAP Earnings per Share of $2.13 and Non-GAAP Earnings per Share of $2.77 – – Reduces 2022 Guidance – WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #CRL–Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2022. For the quarter, revenue was $973.1 million, … [Read more…]

LivaNova Reports Second-Quarter 2022 Results

LONDON–(BUSINESS WIRE)–#advancedcirculatorysupport–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2022. Financial Summary and Highlights1 Revenue of $254.2 million for the quarter, decreased 3.9 percent on a reported basis and increased 0.5 percent on a constant-currency basis, as compared to the prior-year period Revenue, … [Read more…]

United Therapeutics Corporation Reports Second Quarter 2022 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarter of 2021. “I’m extraordinarily … [Read more…]

Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference

BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst—Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022. Canaccord Genuity 42nd Annual Growth Conference Date: Wednesday, August 10, 2022 Time: … [Read more…]

Shaff Fundraising Group (SFG) Launches National Strategic Philanthropy and Engagement Management Consultancy for Nonprofit, Healthcare, and Education Organizations

Nationally Recognized Fundraising Trailblazer Brittany N. Shaff to Spearhead SFG to Provide Personalized, Digital Approach to Nonprofit, Education, and Healthcare Fundraising and Engagement for Sustainable Philanthropic Growth BALTIMORE–(BUSINESS WIRE)–Shaff Fundraising Group (SFG) announced today its launch to provide strategic philanthropy and engagement management consulting. Partnering with nonprofits, independent schools, higher education, and healthcare organizations, SFG … [Read more…]